2nd to 3rd June 2023
The Science Of
HBV Cure
Meeting 2023
9:00 am to 5:00 pm (SGT)
The Science Of Hbv Cure Meeting 2023
REGISTRATION FOR The Inaugural Combined GIHep & Singapore Hepatology Conference includes The Science of HBV Cure 2023.
HBV Cure 2023 will feature an extensive line up of World Renowned Experts from Academic and Industry in the Science of Hepatitis B Cure. They will share and provide a comprehensive update on their research works.
Virtual option not currently available.
The Science of HBV Cure Meeting 2023 Scientific Programme
Who Should Attend?
HBV Cure 2023 is designed for Scientists (virologists, Immunologists), Clinician Scientists, pharmacists and Industry Experts, to exchange information on the latest research, discuss new developments in the cure for Hepatitis B Virus – a disease which still plagues hundreds of millions of people.
Call for Abstracts
We invite all interested parties to present their research papers. Click on bellowAbstracts and Posters for further information.
Abstracts will be reviewed by the Abstract Selection Committee and accepted submissions will be posted on Abstract & Poster Gallery in our website and in the Poster Hall.
Some travel grants will be available to selected Presenters.
June, 2023
2
| Programme | Time (SGT) |
|---|---|
| Welcome Remarks by the Conference Chairman | 10:00 – 10:10 |
| Opening Symposium: Overview of HBV Functional Cure Moderators: Prof. Lim Seng Gee View Bio |
|
| Opening Lecture: Are we winning the battle against CHB? Prevention vs treatment – Prof. Geoffrey Dusheiko, UK View Bio |
10:10 – 10:30 |
| ICE-HBV strategy for functional cure – Prof. John Tavis, USA View Bio |
10:30 – 10:50 |
| Virologal Insights into functional cure Moderators: Prof. Peter Revill View Bio and Prof. John Tavis |
|
| Overview of virology of HBV and targets for therapy – Prof. John Tavis, USA View Bio |
10:50 – 11:10 |
| HBsAg loss: cccDNA silencing, loss or both? – Prof. Massimo Levrero, France View Bio |
11:10 – 11:30 |
| Directly Targeting cccDNA: are we there yet? (recording) – Prof. Fabien Zoulim, France View Bio |
11:30 – 11:50 |
| HBV Viral Integration : Implications for a HBV Cure – Dr. Thomas Tu, Australia View Bio |
11:50 – 12:10 |
| Free Paper: Long-read DNA sequencing reveals large reduction in HBV integration burden in HBsAg-negative patients – Dr. Cameron Soulette, Gilead Sciences Inc View Bio |
12:10 – 12:25 |
| Free paper: Illuminating the Live-Cell Dynamics of Hepatitis B Virus covalent closed circular DNA using CRISPR-Tag – Dr. Xiaonan, Zhang, University of Canberra, Australia |
12:25 – 12:40 |
| Lunch | 12:40 – 13:20 |
| Immunological insights into functional cure Chair and Moderator: Prof. Markus Cornberg and Prof. Jonathan Karn |
|
| Interrogating the intrahepatic microenvironment using FNA – Dr. Loey Mak, Hong Kong View Bio |
13:20 – 13:40 |
| The liver transcriptome and HBV functional cure (recording) – Dr. Ram DasGupta, Singapore View Bio |
13:40 – 14:00 |
| Can innate immune mechanisms lead to HBV cure: lessons from HIV – Prof. Jonathan Karn, USA View Bio |
14:00 – 14:20 |
| Free Paper: Decreased intrahepatic NK exhaustion and increased activation with decreasing HBsAg levels in CHB patients – Dr. Sriram Narayanan View Bio |
14:20 – 14:35 |
| Strategies to reduce viral replication Chair and Moderator: Prof. Geoff Dusheiko and Dr. Loey Mak |
|
| Capsid inhibitors: where are they in the combination for HBV cure? – Prof. Man Fung Yuen, Hong Kong View Bio |
14:35 – 14:55 |
| Nucleoside analogues: are the necessary for functional cure? – Prof. Henry Chan, Hong Kong View Bio |
14:55 – 15:15 |
| Invited Oral & Free Paper Presentations | |
| Invited Presentation: Development of a Highly Potent Next Generation Core Inhibitor for the Treatment of Chronic Hepatitis B Infection (Recording) – Dr. Katie Kitrinos, Assembly Biosciences Inc View Bio |
15:15 – 15:30 |
| Free paper: Comparison of hepatitis B reactivation in patients with resolved hepatitis B infection receiving rituximab or non-rituximab based immunosuppressive therapy: does the presence of anti-HBs antibody reduce the risk of reactivation? – Dr. Valerie Shu Xian Yeap, Singapore |
15:30 – 15:45 |
| Invited Presentation: ASC22 (Envafolimab) a First-in-Class subcutaneously administered Antibody for HBV functional cure: Learnings from pre-clinical and clinical studies – Dr Jinzi Wu, Acletis Pharma Inc. |
15:45 – 16:00 |
| Tea Break | 16:00 – 16:15 |
| Viewpoint Chair and Moderator: Prof. Ed Gane and Prof. Pietro Lampertico |
|
| Achieving functional cure without immunotherapy – Prof. Pei-Jer Chen View Bio |
16:15 – 16:35 |
| A roadmap for Biomarkers for HBV functional cure – Prof. Peter Revill, Australia View Bio |
16:35 – 16:55 |
| Invited Oral & Free Paper Presentations | |
| Invited Presentation: HBsAg Next Qualitative assay on-therapy reactivity predicts HBsAg rebound 24-weeks after therapy discontinuation – Dr. Mark Anderson, Abbott Diagnostics View Bio |
16:55 – 17:10 |
| Free paper: Deep Serum Proteome Profiling Revealed Novel Prognostic Markers for HBsAg Loss – Dr Zi Jie Lim, Singapore |
17:10 – 17:25 |
| Invited presentation: Exploratory Biomarkers for HBV – insights gained and future directions – Dr. Gavin Cloherty, Abbott Diagnostics View Bio |
17:25 – 17:40 |
| Closing remarks | 17:40 – 17:50 |
June, 2023
3
| Programme | Time (SGT) |
|---|---|
| Special Lecture Chair and Moderator: Prof. Peter Revill and Prof Pei Jer Chen |
|
| Absolute cure : a dream coming closer? – Prof. Fabien Zoulim View Bio |
09:10 – 09:30 |
| Reducing viral antigens Chair and Moderator: Prof. Peter Revill and Prof Pei Jer Chen |
|
| Anti-sense RNA strategies: ASO versus siRNA – Prof. Man Fung Yuen View Bio |
09:30 – 09:50 |
| Removing viral antigens using monoclonal antibodies – Prof. Ed Gane View Bio |
09:50 – 10:10 |
| Invited Presentation: The role of NAPs in HBV Functional Cure – Dr. Andrew Valliant, Replicor Inc View Bio, |
10:10 – 10:30 |
| Tea Break | 10:30 – 10:45 |
| Invited Oral & Free Paper Presentations Chair and Moderator: Prof. Peter Revill and Prof. Pei Jer Chen |
|
| Invited Presentation: Phase 1 data on Roche Assets in HBV – Dr. Klaus Kuhlbusch, Roche View Bio |
10:45 – 11:00 |
| Free Paper: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus (HBV) infection: changes in HBV DNA in patients not on stable nucleos(t)ide analogue therapy – Prof. Man Fung Yuen View Bio |
11:00 – 11:15 |
| Invited Presentation: The Development of VIR-2218 and VIR-3434 for the Treatment of chronic HBV Infection – Dr. Carey Hwang, Vir Biotechnology, Inc View Bio |
11:15 – 11:30 |
| Invited presentation: Update on AB-729, an RNAi therapeutic in Phase 2 development as a key component of a functional cure strategy for cHBV (Recording) – Dr Karen Sims, Arbutus Biopharma Corporation |
11:30 – 11:45 |
| Q&A | 11:45 – 12:00 |
| Novel Therapies Chair and Moderator: Prof. Geoff Dusheiko & Dr. Thomas Tu |
|
| Novel agents and novel mechanisms – Prof. Ed Gane View Bio |
12:00 – 12:20 |
| Free paper: First demonstration of CRISPR-CAS13B-mediated suppression of Hepatitis B Virus replication and Protein Expression – Pre-Clinical investigations of a new therapeutic approach – Ms Laura McCoullough, Australia |
12:20 – 12:35 |
| Q&A | 12:35 – 12:45 |
| Lunch | 12:45 – 13:30 |
| Delta Cure: Chair and Moderator: Prof. Massimo Levrero |
|
| What is Delta cure and how to achieve it? – Prof. Pietro Lampertico View Bio |
13:30 – 13:50 |
| Immunology Forum Chair and Moderator: Prof. Ed Gane and Prof. Antonio Bertoletti |
|
| Adaptive immune recovery in patients with low qHBsAg – Prof. Markus Cornberg View Bio, Germany |
13:50 – 14:10 |
| Landscape of immune based therapies for functional cure – Prof. Antonio Bertoletti View Bio |
14:10 – 14:30 |
| Can combination immunotherapy lead to improved functional cure – Prof. Markus Cornberg View Bio |
14:30 – 14:50 |
| Invited Presentation: A Novel Arenavirus-Vectored Therapeutic Vaccine for HBV Cure. – Dr. Scott Balsitis, Gilead Sciences Inc View Bio |
14:50 – 15:05 |
| Invited Presentation: How will HBV Cures get to patients? The varied challenges of access to medicines in the 21st century – Ms Cammy Yuen, GlaxoSmithKline |
15:05 – 15:20 |
| Q&A | 15:20 – 15:40 |
| Tea Break | 15:40 – 16:00 |
| Combination Therapy Forum 1
Chair and |
|
| When should we start immunotherapy? De novo combination or sequential? – Prof. Geoff Dusheiko, Prof. Markus Cornberg, Prof. Antonio Bertoletti, Prof. Ed Gane, Dr. Carey Hwang, Prof. Jonathan Karn |
16:00 – 16:40 |
| Combination Therapy Forum 2
Chair and |
|
| Should siRNA or ASO be the backbone for combination therapy in functional cure? – Prof. Peter Revill, Prof. Yuen Man Fung, Prof. Massimo Levrero, Prof. John Tavis, Prof. Henry Chan, Dr. Dickens Theodore, Dr. Klaus Kuhlbusch |
16:40 – 17:20 |
| Closing remarks from Chairman | 17:20 – 17:30 |